Jump to content


  • Please log in to reply
3 replies to this topic

#1 SkunkyAroma


    Skunk Head

  • Moderators
  • 1789 posts

Posted 24 January 2016 - 05:25 PM

​Cannabis for Migraine Relief

by Sean Williams
Jan 24, 2016

Image source: Pixabay.

It's an ailment that often flies under the radar, but it costs employers $13 billion in lost productivity and workers 113 million in lost work days each year. It's also the world's eighth most disabling disease and affects 38 million men, women, and children in the United States. Despite these eye-popping facts, courtesy of the Migraine Research Foundation, migraine headaches remain very much a mystery to researchers.

This isn't to say solutions aren't in the works for migraine sufferers. There are medications on pharmacy and over-the-counter shelves designed to alleviate migraine symptoms, as well as therapies being developed by drugmakers right now that are attempting to tackle the disease. But when push comes to shove, there is no cure for what migraine sufferers go through when an episode, which can last anywhere from four to 72 hours, strikes. It means the search for a breakthrough medicine continues.

Is this illegal drug the answer to curbing migraine headaches?
However, as published in the journal Pharmacotherapy earlier this month, and via the National Institutes of Health's online library of medicine, four researchers in Colorado believe they may have found another potentially effective treatment for migraines. The catch? This treatment involves the use of a currently illegal drug: marijuana.

Image source: Pixabay.

Researchers from the University of Colorado Anschutz Medical Campus and Gedde Whole Health used two medical marijuana specialty clinics in Colorado to test 121 patients with a primary diagnosis of migraine headaches between January 2010 and September 2014. The idea was to determine what effect, if any, marijuana had on reducing migraine frequency over the course of the month with the assumption that cannabinoids within the cannabis plant could positively affect serotonin production and reduce the severity of, or completely eliminate, a migraine. Prior research has suggested a connection between low serotonin levels and migraine frequency.

The results demonstrated a statistically significant advantage for marijuana when it came to migraine frequency reduction. Migraine frequency for the tested patients dropped from 10.4 per month to just 4.6 per month, a 56% clinical benefit. The study notes that most patients used more than one form of marijuana, and positive effects were noted in 48 patients, or roughly 40%. This included 14 patients who were able to abort their migraine headache completely. Additionally, inhaled marijuana was the most common use method attributed to aborted migraine headaches.

Conversely, 14 patients, or about 12%, reported negative effects during the study, which included somnolence (i.e., a state of extreme drowsiness) and difficulty in controlling the effects of marijuana based on the timing and intensity of the dose. Most of the negative effects of the study were tied to marijuana edibles.

Ultimately, researchers concluded that the statistically significant result merits further research. No causation can be determined just yet, but it's an interesting and encouraging start for marijuana as it relates to migraine research.

Image source: GW Pharmaceuticals.

Marijuana notches another clinical victory
This isn't marijuana's first positive result in clinical studies, either.

In May 2013, an abstract study published in The American Journal of Medicine looked at more than 4,600 adults, 579 of which were current marijuana users, and 1,975 which have previously used marijuana. It showed that current marijuana use was tied to a 16% reduction in fasting in insulin levels and a 17% reduction on HOMA-IR, which is associated with insulin resistance. The takeaway is that marijuana could be potentially effective in treating type 2 diabetes by promoting improved glycemic balance.

More recently, a study was published in the Journal of Leukocyte Biology from researchers at the University of South Carolina School of Medicine, which showed that the cannabinoid THC may lengthen the time it takes for incompatible organs to be rejected by a patient. Keep in mind that this study was conducted on mice and not humans, but there was a noted delay in rejection for the mice given THC compared to the placebo.

Even publicly traded drug developers are getting in on the act. GW Pharmaceuticals (NASDAQ:GWPH), which has discovered more than five dozen cannabinoids and develops therapies that work with the cannabinoid receptor system found within our bodies, is working on a potentially groundbreaking treatment for two rare types of childhood-onset epilepsy. In clinical studies, GW Pharmaceuticals' Epidiolex, a cannabinol-based drug, reduced seizure frequency by more than 50% for Lennox-Gastaut and Dravet syndrome patients.

This represents just a handful of the benefits marijuana has demonstrated in prior clinical studies.

#2 SkunkyAroma


    Skunk Head

  • Moderators
  • 1789 posts

Posted 24 January 2016 - 07:57 PM

   more recently data has begun to accumulate that psilocybin mushrooms may successfully reduce the incidence of cluster headaches for weeks or months and may also reduce the pain during an attack.

#3 SkunkyAroma


    Skunk Head

  • Moderators
  • 1789 posts

Posted 03 February 2016 - 02:42 AM


#4 SkunkyAroma


    Skunk Head

  • Moderators
  • 1789 posts

Posted 19 August 2017 - 07:41 PM


New Study: Cannabis Just as Effective on Migraines as Pharmaceuticals


By Duke London


June 30th, 2017

According to a new study out of Italy, the cannabinoids in marijuana are equally effective in preventing migraines as the pharmaceuticals available on the market today.

The findings of the study, led by Dr. Maria Nicolodi, were presented at the 3rd Congress of the European Academy of Neurology this week in the Netherlands. Dr. Nicolodi and her team set out to determine if cannabinoids could not only replace existing pharmaceutical drugs used to prevent migraine attacks but also in the treatment of acute pain related to the migraines.

The belief that migraines are simply more intense headaches is categorically false. Migraines affect roughly a billion people, making them the third most common illness worldwide. In the United States, almost 40 million Americans suffer from the throbbing affliction that can last up to 72 hours. For many, migraines are accompanied by extreme light and sound sensitivity, nausea, dizzy spells, and loss of feeling in the extremities. Finding a therapeutic solution that heals without adding a laundry list of other side effects is a crucial endeavor.

Before Dr. Nicolodi’s team could administer both types of medicine to the 48 subjects, her team had to determine the proper dosage to supply for a comparable effect to existing medication on the market. Initially, researchers began the trial by issuing a 10mg (19 percent THC and 9 percent CBD) dose orally to subjects. Researchers determined that no dosage under 100mg proved successful in combating migraines. Once Dr. Nicolodi’s team raised the dosage to 200mg, patients experienced 55 percent less acute pain.

In the second phase of the study, 79 subjects with a history of chronic migraines were given one of two drugs. Some patients were given the 200mg cannabinoid compound that proved successful in the early trials of the study, while others were administered 25mg of amitriptyline, an antidepressant commonly prescribed to migraine sufferers. After three months of taking one of the two drugs each day, the patients who were taking the cannabis compound experienced a higher drop in migraine attacks than the subjects who were issued amitriptyline.

Furthermore, when the attacks did occur, the cannabinoids stifled the acute pain experienced by patients by 43.5 percent. The cannabinoid compound also showed an ability to greatly decrease the inherent side effects of migraines such as stomach aches.


0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users